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Abstract
: Pre-treatment severity is a key indicator of prognosis forBackground
those with depression. Knowledge is limited on how best to encompass
severity of disorders. A number of non-severity related factors such as
social support and life events are also indicators of prognosis. It is not clear
whether this holds true after adjusting for pre-treatment severity as a) a
depressive symptom scale score, and b) a broader construct
encompassing symptom severity and related indicators: “disorder severity”.
In order to investigate this, data from the individual participants of clinical
trials which have measured a breadth of “disorder severity” related factors
are needed.
: 1) To assess the association between outcomes for adults seekingAims
treatment for depression and the severity of depression pre-treatment,
considered both as i) depressive symptom severity only and ii) “disorder
severity” which includes depressive symptom severity and comorbid
anxiety, chronicity, history of depression, history of previous treatment,
functional impairment and health-related quality of life.
2) To determine whether i) social support, ii) life events, iii) alcohol misuse,
and iv) demographic factors (sex, age, ethnicity, marital status, employment
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 and iv) demographic factors (sex, age, ethnicity, marital status, employment
status, level of educational attainment, and financial wellbeing) are
prognostic indicators of outcomes, independent of baseline “disorder
severity” and the type of treatment received.
: Databases were searched for randomised clinical trials (RCTs)Methods
that recruited adults seeking treatment for depression from their general
practitioners and used the same diagnostic and screening instrument to
measure severity at baseline – the Revised Clinical Interview Schedule;
outcome measures could differ between studies. Chief investigators of all
studies meeting inclusion criteria were contacted and individual patient data
(IPD) were requested.
: In total 13 RCTs were found to meet inclusion criteria. TheConclusions
Dep-GP database was formed from the 6271 participants. This protocol
outlines how these data will be analysed.
: PROSPERO   (01/04/2019)Registration CRD42019129512
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Introduction
One in 20 adults across the globe will experience an episode of 
major depression every year (Thornicroft et al., 2017), most 
of whom will not receive any treatment (Olfson et al., 2016; 
Thornicroft et al., 2017). For those that do get treatment the 
majority will either not reach remission or it will take a number 
of trials of different treatments before they do (Kessler, 2018; 
Rush et al., 2006). Not reaching full remission is one of the 
strongest predictors of relapse and recurrence (Buckman et al., 
2018). There is a lack of knowledge of prognosis independent 
of treatment and within different types of treatment, and there-
fore a lack of evidence with which to make informed choices of 
whether any active treatment should be trialled, or which type 
of treatment to trial at any given point, for any given individual 
(e.g. Cohen & DeRubeis, 2018).
In order to reduce the burden of depression it is imperative that 
we understand more about the response to treatments, and their 
limits, to better consider the risk for poor prognostic outcomes. 
One major focus has been on the effect of baseline severity on 
outcomes. That severity is related to outcome holds with the 
‘common-sense’ view of most illnesses, depression included, 
but as recommended by Leucht and colleagues (Leucht et al., 
2015) the consideration of prognosis needs to account for more 
than just the number or intensity of depressive symptoms. 
Studies considering the role of pre-treatment depressive severity 
have typically been limited to group level analyses (e.g. Kirsch 
et al., 2008) so have been unable to consider severity beyond a 
score on a depressive symptom measure. In so doing, these 
studies have been unable to account for the seriousness of the 
presentation of depression (e.g. Leucht et al., 2012)). Such 
studies and others that have utilised individual patient data have 
also typically been limited to a narrow band of treatment types 
(e.g. Fournier et al., 2010) and to studies with small sample 
sizes (e.g. Cohen et al., 2019), limiting their generalizability 
(Rothwell, 2005).
Several factors which may be considered in conjunction with 
depressive symptom scale scores as part of “disorder severity”, 
and could potentially act through the same mechanisms on 
outcome (e.g. Fried & Nesse, 2014), have also been found 
to be important in prognostic models. For example: factors 
related to past experiences of depression, duration or chro-
nicity (Fournier et al., 2009), a history of depression (e.g. 
Chekroud et al., 2016), and a history of previous treatments 
for depression (e.g. DeRubeis et al., 2014); and functional 
impairment (e.g. Delgadillo et al., 2016; Saunders et al., 2016) 
are all indicators of prognosis.
There is a lack of agreement on the prognostic role of anxi-
ety symptoms and of comorbid anxiety disorders for those with 
depression despite agreement that symptoms of anxiety are 
common among those with depression either as part of their 
depressive episode or another comorbid disorder (e.g. Kessler 
et al., 2005; Sartorius et al., 1996). Somatic anxiety and 
avoidance related symptoms of agoraphobia (Chekroud et al., 
2016) have been found to be prognostic for those treated with 
antidepressant medications (ADM) but not in those treated with 
psychological therapies (e.g. Lutz et al., 2006). Symptoms of 
generalised anxiety disorder and phobias have also been found 
to be predictive of outcomes in some clinical cohorts (Saunders 
et al., 2019; Saunders et al., 2016); but not in others (Delgadillo 
et al., 2016). Given the high rates of comorbidity and the 
co-occurrence of depressive and anxious symptoms even at 
sub-clinical levels, it would be useful to know whether the 
prognostic effects of anxiety symptoms and disorders (collec-
tively or individually) operate independently from depressive 
symptom severity, “disorder severity”, and independent of the 
type of treatment given, if any. One potential explanation for 
the somewhat contradictory findings on the role of anxiety 
symptoms and disorders on the prognosis of patients with 
depression is that many studies have used different scales to 
measure the same and indeed different anxiety conditions. 
Consistency in the measurement of such factors might allow 
for a more definitive investigation of the prognostic role of such 
symptoms and disorders.
There is similar disagreement regarding alcohol misuse as an 
indicator of prognosis, it is also highly comorbid with depression 
but has been less well studied (e.g. Weaver et al., 2003). Some 
studies have suggested that alcohol misuse (excluding alcohol 
dependence) is a prognostic indicator of treatment outcomes for 
those with depression (Clarkson et al., 2016), but others have 
suggested that it is unrelated to treatment outcomes (Boschloo 
et al., 2012) and instead is predictive only of dropping out of 
treatment (Buckman et al., 2018). There are several other factors 
that may be related to depression treatment outcomes but 
again, the effects have been less well studied. These include 
health-rated quality of life (e.g. Huibers et al., 2014), social 
support (e.g. Hallgren et al., 2017) and life events recent 
to the present episode (e.g. DeRubeis et al., 2014; Fournier 
et al., 2009). This leaves the question then of whether or 
not these factors are indicative of prognosis independent of 
baseline severity (whether this encompasses only depressive 
symptoms (“symptom severity”) or the wider construct of 
“disorder severity” including other factors noted above), and 
independently of treatment. In addition, a number of demographic 
factors have been found to be important in predictive models of 
depression outcomes alongside symptom severity, including: 
age (e.g. Delgadillo et al., 2016; Fournier et al., 2009); gender 
(Saunders et al., 2016); ethnicity (e.g. Chekroud et al., 2016; 
Saunders et al., 2016); marital status (e.g. Fournier et al., 
2009); employment status (e.g. Chekroud et al., 2016; Fournier 
et al., 2009); level of educational attainment (e.g. Chekroud 
et al., 2016); and markers of socio-economic status or financial 
stability/security (e.g. Saunders et al., 2016). However, whether 
these factors are indicators of prognosis independent of sever-
ity (either as just depressive symptoms or the wider construct 
encompassing more than just depressive symptoms) remains to 
be seen. Here, we use the phrase independent of treatment 
to highlight that we wish to investigate factors that affect 
outcome regardless of any treatments rather than trying to 
identify factors that help predict response to a given type of 
treatment or those that predict differential response to two or 
more treatments.
Over the last three years a number of authors of the current 
article have worked to collect individual participant data (IPD) 
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from randomised clinical trials (RCTs) of any treatment for 
depression, recruited from primary care services/general prac-
tice, that used the same clinical interview schedule (the CIS-R) 
to measure “disorder severity” factors, determine diagnoses, 
and capture symptoms across a range of depressive and anxious 
disorders. This article explains how that IPD dataset was 
formed and describes a protocol for a series of analyses of it.
Aims and objectives
1)     To determine whether certain “disorder severity” factors 
are indicators of prognosis, independent of treatment, 
and independent of baseline depression symptom scale 
scores. These are i) chronicity of depression at base-
line; ii) a history of depression; iii) a history of any pre-
vious treatment for depression; iv) a history of ADM 
treatment; v) anxiety symptom severity; vi) presence of 
and number of comorbid anxiety disorders; vii) duration 
of anxiety problems; viii) functional impairment; and 
ix) health-related quality of life.
2)     To determine whether or not the following are indicators 
of prognosis independent of severity of depression as 
measured in both ways outlined in 1 above - symptom 
severity, and “disorder severity”:
i)         social support
ii)         the occurrence of recent stressful life events
iii)        alcohol misuse
iv)          demographic factors (age, gender, ethnicity, 
employment status, marital status, highest level 
of educational attainment, and financial wellbeing 
including housing status)
Methods
Identification and selection of studies
Studies were identified using a combination of keyword and 
subject heading searches on the bibliographic databases below, 
hand-searching through the references of studies identified in the 
searches, and by contacting experts for unpublished or missed 
studies. Searches were run on the Cochrane CENTRAL Trial 
Register (searched on 20th March 2019), Embase 1947 to 2019 
Week 12, International Pharmaceutical Abstracts 1970 to 
March 2019, Ovid MEDLINE 1946 to March Week 3 2019, and 
PsycINFO 1806 to March Week 3 2019. Search terms included 
variations of phrases such as “depression” or “major depression”, 
“RCT” or “Randomised Controlled Trial” or “Clinical Trial”, 
and “CIS-R” or “Clinical Interview Schedule”. Full details of 
the searches are provided as Extended data (Buckman, 2019).
A single reviewer (JB) screened titles and abstracts of 
potentially eligible studies returned by the searches, those that 
were potentially relevant to the review were then read in full 
and judged against inclusion/exclusion criteria. Uncertainties in 
inclusion/exclusion were discussed with two other reviewers 
(GL and SP). Relevant studies were then read in full by all three 
reviewers before reaching consensus.
Inclusion & exclusion criteria
Studies were included if they were randomised clinical trials 
(RCTs) of unipolar depressed adults (aged 16 or over), had at 
least one active treatment arm and used the CIS-R (Lewis et al., 
1992) at baseline to measure symptoms of anxiety and depres-
sion and to determine diagnoses. While all studies had to use 
the CIS-R at baseline, outcome measures could differ between 
studies. Studies were only included if the protocol or main 
publications from the study were published in the English 
language and if they recruited from General Practices in the 
UK.
Studies were excluded if they did not meet the above criteria 
and if they: included patients with depression as a secondary 
diagnosis in studies of adults with personality disorders, psychotic 
conditions, or neurological conditions; were studies of adults 
with bi-polar or psychotic depressions; were studies of children 
or adolescents; were feasibility studies only; or did not recruit 
participants from General Practices in the UK.
Measures
The relevant measures included in the identified studies are:
The CIS-R (Lewis et al., 1992): consists of 14 symptom subsec-
tions scored 0–4 covering core features of depression, depres-
sive thoughts (scored 0-5), fatigue, concentration/forgetfulness, 
and sleep, generalized anxiety, worry, irritability, obsessions, 
compulsions, health anxiety/somatic concerns, phobic anxiety 
(split into agoraphobia, social phobia, and specific phobia), and 
panic. A final section measures general health, impairment and 
weight change. The total score ranges from 0–57 with a cut-off 
of ≥12 used to indicate likely common mental disorder, primary 
and secondary diagnoses using ICD-10 criteria are given as are 
binary indictors of diagnosis for all the disorders assessed.
Beck Depression Inventory (BDI-II: Beck et al., 1996)): used to 
measure depressive symptoms, each item is scored 0–3 with a 
maximum score obtainable of 63. A cut-off of ≥10 is used indicate 
significant symptoms of depression.
Patient Health Questionnaire (PHQ-9: Kroenke et al., 2001) is a 
9-item depression screening measure. Items are scored 0–3, a 
cut-off of ≥10 is used to indicate “caseness” for depression.
Hospital Anxiety and Depression Scale (HADS: Zigmond & 
Snaith, 1983): measures symptoms on two subscales, depression 
and anxiety. The cut-off for caseness on the depression subscale 
is ≥8.
General Health Questionnaire (12-item version) (GHQ-12: 
Goldberg, 1992): a cut-off of ≥2 is used to indicate the presence 
of common mental disorders.
Edinburgh Postnatal Depression Scale (EPDS: Cox et al., 1987)): 
measures symptoms of depression focussed on women in the 
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post-natal period, scores of ≥13 are indicative of a depressive 
episode
Social Support: an 8-item instrument assessing the degree to 
which participants rated the social support of their friends and 
family in each of the following domains: 1) being accepted for 
who one is; 2) feeling cared about; 3) feeling loved; 4) feeling 
important to them; 5) being able to rely on them; 6) feeling 
well supported and encouraged by them; 7) being made to feel 
happy by them; and 8) feeling able to talk to them whenever 
one might like. These were adapted by authors of RCTs (e.g. 
Kessler et al., 2009) included in this IPD from items of the 
Medical Outcomes Study Social Support Survey: (Sherboune & 
Stewart, 1991). Items are scored 1–3, with total scores ranging 
from 8–24; higher scores indicate higher levels of perceived social 
support.
Life events: the Social Readjustment Rating Scale (Holmes & 
Rahe, 1967): participants are asked to say yes/no to whether 
they have suffered any of nine events within the last six months 
e.g. a death/bereavement; being physically attacked/injured; 
or going through a divorce/separation. Each item is scored yes 
(1) or no (0) and the total score is the sum of all the items.
Alcohol use: the alcohol use disorder identification test pri-
mary care version (AUDIT-PC: Piccinelli et al., 1997) was used 
to assess alcohol misuse, this includes five items scored 0–4. A 
cut-off of ≥5 indicates hazardous alcohol use that may be harmful 
to one’s health.
Health related quality of life: EQ-5D-3L & EQ-5D-5L: 
(Herdman et al., 2011)): the EQ-5D is a generic measure of 
health status in five domains – mobility; self-care; usual activi-
ties; pain/discomfort; and anxiety/depression. Each domain in 
the 3L version has three response categories ranging from no 
problem present (1) to extreme problems in the given domain 
(3), the 5L version has five response options ranging from “I 
have no problems…” (1) to “I am unable to…” or “I have/am 
extreme/extremely…” (5). A total score is derived from sum-
ming the score on the five items with higher scores indicating 
more severe health problems than lower scores. A cross-walk 
of scores from the 3L and 5L versions will be used to derive a 
continuous index score representing the EQ-5D total score in the 
present study (van Hout et al., 2012).
Characteristics of the included studies
In total, 13 RCTs were identified as meeting inclusion criteria 
for the IPD, of which 12 have provided individual patient-data 
and the remaining one is in the process of providing these 
data, see Figure 1. A description of each study can be found in 
Table 1 and descriptive statistics and degrees of missingness 
for key predictor and outcome variables discussed below are 
presented in the Extended data (Buckman, 2019). Integrity of 
the data for each study was checked with the study team and 
against details published about each study, discrepancies were 
discussed and investigated in conjunction with each study team 
until satisfactory explanations were found and updated data were 
provided if appropriate and if required.
Ethical considerations and trial registrations
All studies included in the Dep-GP database were granted ethical 
approvals by NHS Research Ethics Committees. Specific ethical 
approvals and trial registration details are given in Extended data 
(Buckman, 2019).
Data analysis plan
End-point data. Of the included studies, 11 collected endpoint 
data between three and four months post-baseline (see Table 1), 
this will be the primary endpoint of interest for the analyses out-
lined in this protocol Additional end-points between six and 
eight months, and nine and 12 months post-baseline will be used 
for sensitivity analyses (see Table 2). Endpoints prior to three 
months or after 12 months will be excluded from the present 
analyses.
Outcomes
Primary outcomes. The primary outcome for the present 
analyses will be the score on the primary depressive symp-
tom measure used at 3–4 months post-baseline. Scores on the 
different measures of depressive symptoms used across the 
studies at the endpoints will be z-score standardised. This will 
be done for each symptom measure using the mean and stand-
ard deviation (SD) at 3–4 months pooled across all arms of all 
studies that reported that symptom measure at that time. The 
same mean and SD will be used to create z-scores for secondary 
outcomes at 6–8 and 9–12 months post-baseline.
A second primary outcome will be the log of 3–4 month 
post-baseline depression scale scores, without standardising 
across the measures. This will allow for the consideration of 
proportional change in symptom scores (e.g. Button et al., 
2015)
Secondary outcomes. In any analysis where the only outcome 
measures used in the studies of the Dep-GP database were the 
BDI-II or the PHQ-9 a secondary outcome will be a conversion 
of those two measure scores to the PROMIS T-score (Choi 
et al., 2014). This will be achieved using cross-walk tables 
derived from an item-response theory based analysis of several 
depression symptom measures (Choi et al., 2014).
Additional secondary outcomes will be partial remission on each 
of the primary outcome measures used in each study (scores 
below the cut-off for caseness on each measure as described in 
Measures section above), and the proportion of participants that 
dropped-out/withdrew from each study at each time-point.
Prognostic indicators under consideration
1.     “Disorder severity” of depression at baseline, from 
self-reported:
•    scores on the depressive symptom measures detailed 
above
•    the sum of the scores on the depressive sub-scales 
of the CIS-R
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Figure 1. Flow diagram of study selection.
•    the sum of the scores on the non-depressive/anxiety 
sub-scales of the CIS-R combined, and individually 
by subscale
•    the number and type of comorbid anxiety disorders
•    the duration of depression
•    the duration of anxiety
•    whether or not participants have a history of depres-
sion
•    whether or not participants have a history of 
previous treatment for depression, and whether or 
not participants have a history of ADM treatment
•    whether or not participants were experiencing 
significant functional impairment at baseline
•    Health-rated quality of life at baseline.
2. Demographic factors
•    Age
•    Gender
•    Ethnicity
•    employment status
•    marital status
Records identified from electronic
database searching (n= 124)
Cochrane CENTRAL 27; Embase 27; IPA
1; MEDLINE 20; PsycINFO 49
Additional records identified
through other sources (n= 1)
  1 from correspondence with experts
0 From hand searching of references
Records after duplicates removed
(n=85)
Records screened
(n= 85)
Studies asessed for
eligibility
(n= 57)
RCTs included in IPD
(n = 13)
Records excluded (n=28)
Records excluded (n=44)
5= irrelevant to research question
5= Protocols not trials
4= Pilot studies supersed by another
full trial also returned in search
14= Secondary publications/duplicates
27= Not RCTs
5= Not studies of depression
4= Small feasibility trials
4= Not recruited from GP or not in UK
4= Studies of children
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initial depressive symptom severity will be investigated as 
potential confounders within each study. Treatment allocation, 
i.e. the randomisation in each study will be controlled for in all 
multivariable models.
Data handling and data management
Pre-processing
Data from the 13 trials were received and cleaned on an 
individual study basis before combining all studies into a single 
aggregated dataset.
A number of baseline variables were re-categorised into higher-
order categories due to small numbers, see Table 3. Of note, 
there was poorer data-coverage across the IPD on information 
about the number of past depressive episodes than there was on a 
separate question about whether or not the participant had any 
previous episodes, see Extended data (Buckman, 2019).
Further pre-processing for the analyses specified below will be 
considered. The distributions of all variables will be inspected 
prior to imputation (discussed further below). Continuous 
variables that are non-normally distributed will be transformed 
to normality prior to imputation. If transformation is required of 
the prognostic indicators these will only be log transformed in 
order that the interpretation of their effects is sensible. If log- 
transformation does not result in approximate normality of 
the distribution of these variables, predictive mean matching 
(Morris et al., 2014) will be used for imputation of missing 
data as part of the multiple imputation with chained equations 
approach discussed further below.
Missing data
Missing data will be imputed using multiple imputation with 
chained equations (MICE) in Stata 15.0 (StataCorp, 2017). 
This approach uses regression models to impute missing 
values. A number of imputed datasets (here we will use 50) are 
produced to reflect the uncertainty/variability in the imputation 
process. If data are not reasonably able to be log transformed 
to meet normality assumptions, predictive mean matching 
(PMM) via a k-nearest neighbours approach will be used as it is 
considered to be more appropriate for non-normal continuous 
variables (Horton & Lipsitz, 2001), here we will use k=10. 
Linear regression will be used for approximately normally 
distributed continuous variables, logistic regression models 
will be used for binary variables, and ordinal and multinomial 
regression models will be used for ordered and unordered 
categorical variables respectively. All imputation models will be 
built using data on baseline and outcome variables following 
conventions (e.g. Royston & White, 2011). Only variables with 
less than 50% missing data will imputed (see Extended data for 
degrees of missing by variable (Buckman, 2019)). All impu-
tation models will be run to produce 50 imputed datasets. If 
the primary analysis (detailed below) shows that results differ 
considerably when studies with systematically missing baseline 
data are included/excluded from the meta-analytic models, then 
a separate imputation approach will be taken to impute these 
systematically missing data: multiple imputation with multilevel 
random effects for study (e.g. Resche-Rigon et al., 2013).
Table 2. Endpoints and time from baseline 
in weeks in each study in the Dep-GP 
database.
Endpoint and time from 
baseline in weeks (w)
3–4m 6–8m 9–12m
Study 12–18w 24–32w 36–52w
AHEAD 12w 26w 52w
CADET 16w 52w
COBALT 12w 26w 36w
CPN-GP 26w
GENPOD 12w
HEALTHLINES 16w 32w 52w
IPCRESS 16w 32w
ITAS 26w
MIR 12w 24w 52w
PANDA 12w
REEACT 16w 52w
RESPOND 18w 44w
TREAD 16w 32w 52w
•    highest level of educational attainment
•    financial wellbeing
•    housing tenure
3.    Social support in all eight domains listed in the Measures 
section above and the total score on the measure.
4.    Life events in all nine domains as discussed in the Measures 
above and the total score.
5.    Total score on the alcohol measure
Confounding factors
Different confounding factors will be considered in relation to 
each prognostic factor under investigation. Determinations 
of which factors to include in the meta-analytic models as 
confounders will be made based on a priori considerations 
of the relationship under investigation and the relationships 
between the confounder and both the prognostic indicator and 
outcome. Only factors that are independently associated with 
both the prognostic factor and the outcome, are not poten-
tially caused by the prognostic factor, and affect the association 
between the prognostic factor and outcome will be considered 
as potential confounders. For example, age is a priori assumed 
to confound the relationship between duration of depression 
and outcome at 3-to-4 months. The presence of any long-term 
physical health condition might be considered a confounder 
in the relationship between health-related quality of life and 
outcome. In addition, research site or centre, and the clinical and 
demographic factors listed above in the prognostic indicator 
section (for analyses in which they are not the predictor of 
interest) will all be investigated as potential confounders. The 
variables used to stratify the randomisation beyond site and 
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Table 3. Categorisation of variables during data pre-processing.
Variable Original categories New categories
Ethnicity White White
Mixed
Other
Black
Asian 
Chinese
Other
Employment Status Full time employed
Employed
Part time employed
Student
Not seeking employment
Retired
House-person
Other
Unemployed jobseeker
Unemployed
Unemployed due to ill-health
Marital Status Married/cohabiting Married/cohabiting
Single Single
Separated
No longer marriedDivorced
Widowed
Highest level of education Degree or higher Degree or higher
Foundation Degree/Diploma
A-level or Diplomas
A-level
GCSE GCSE
Other qualifications
None or Other
No formal qualifications
Financial Wellbeing Living Comfortably
OK financially
Doing alright
Just about getting by Just about getting by
Hard to make ends meet
Struggling financially
Very hard to make ends meet
Long-term Health 
Condition Status None No long-term physical 
health conditions
Mental Health Only
Diabetes
At least one long-term 
physical health condition
Asthma or COPD
Arthritis
Heart Disease
Stroke
Cancer
Kidney Disease
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Software & packages
Stata SE 15 (StataCorp, 2017): ipdmetan (Fisher, 2015) and 
ICE (Royston, 2009), mi impute pmm (Morris et al., 2014) 
packages.
Primary analyses
To investigate Aim 1 linear regression models of the score on 
the depressive symptom scales at 3-4 months post-baseline will 
be built in each study, adjusting for the random allocation in 
each study, baseline depression scale scores in each study, and 
then separately for other “disorder severity” related factors 
listed above. Estimates from each study will then be pooled 
in random effects meta-analyses. A multivariable model of 
outcome will be built considering all of the “disorder severity” 
factors that are significantly associated with outcome after 
adjusting for baseline depressive symptom scale scores alone. 
This will be done initially with only variables that are not 
systematically missing between the studies, such models will 
be built firstly on all studies and then on all studies that do not 
have systematically missing covariates that could otherwise 
have been included in the multivariable model. These models 
will be compared and if there is a considerable difference in 
the effects systematically variables will then be imputed as 
described above. Decisions on which factors to include/exclude 
in the multivariable models will be led by consideration of the 
unique contribution to the models by each variable, the amount 
of variance explained (R2) when modelled with and without 
the given factor, and to tests of the assumptions of linear regres-
sion models. If there are high degrees of multicollinearity the 
variable(s) explaining most variance in outcome will be retained 
in the model while the other(s) is/are removed. Link tests will 
be performed to consider the appropriateness of the linear link 
function. Multivariate normality, homoscedasticity, and overly 
influential data points will be considered by plotting residuals, 
and assessing Cook’s distance in the residuals plotted against 
leverage.
Aim 2 - Separate meta-analyses will be conducted with each of 
the prognostic indicators under consideration (social support, 
life events, alcohol misuse, and the demographic factors 
outlined in the Introduction above), unadjusted and adjusted 
for severity (symptom severity and “disorder severity”) to 
determine whether or not they are indicative of outcome of 
treatment independently from either or both of symptom severity 
and “disorder severity”.
There will therefore be three models of the primary outcome 
built for each prognostic factor assessed and an additional model 
just for the confounding factors and the baseline depressive 
symptom scale scores:
1.    Baseline depressive symptom scale score adjusted for 
confounding factors.
2.    As in 1 but with the addition of each “disorder severity” 
factor (one by one).
3.    As in 1 with the addition of all “disorder severity” 
factors that were significant or otherwise important in 2, 
and then removing factors that are no longer significant.
4.    As in 3 with the addition of the other potential prognostic 
factors (e.g. social support) (one by one).
Meta-analyses will be conducted using the “ipdmetan” package 
in Stata (Fisher, 2015) and displayed using forest plots. All 
meta-analyses will be conducted using a DerSimonian and Laird 
random effects model. This takes into account heterogeneity 
of coefficients between trials. The degree of heterogeneity 
will be assessed using prediction intervals and its impact will 
be assessed using the I2 statistic (Higgins et al., 2003).
Secondary and sensitivity analyses
If heterogeneity between the studies is considered problematic 
e.g. with I2 above 80% or where the effect in one study appears 
to be considerably different from that of all other studies after 
inspecting the forest plot, sensitivity analyses will be performed 
removing studies contributing most to the heterogeneity from 
the meta-analyses to consider their impact on the summary 
statistics. Additional investigations of potential heterogeneity 
between the studies will involve assessing effects in Aim 1 in 
subgroups of patients including those with treatment resistant 
depression compared to those with a first episode and those 
with no history of treatment. Further sensitivity analyses will 
be conducted using the endpoint at 6-to-8 months in bivariate 
meta-analyses in order to include the two studies that did not 
have an endpoint in the 3-to-4 month post-baseline time 
period. This will initially be done only to assess the prognostic 
indication of baseline depressive scale scores adjusted for the 
confounding factors specified. If it is found that this leads to 
considerable variation in the results then this method will be 
similarly used in the analyses of the other potential prognostic 
factors.
In addition to considering the associations between social 
support and outcome as modelled with the total score on the 
social support scale, analyses will be conducted with each of 
the eight domains measured on that scale. Likewise, each of the 
nine domains measured in the life events scale will be considered 
individually.
Sample size and power
The sample size for each of the proposed analyses will be 
dependent on the number of studies identified as relevant to that 
analysis and the degree of systematically missing data across 
the studies on the variables of interest. However, in Dep-GP 
there will be sufficient power to detect effects in all of outlined 
analyses as sample sizes will be beyond the minimum required 
to detect such effects. For example, for 80% power to detect an 
effect of depressive symptom severity of the same size found 
in a prior analyses (R2 of 0.09: Delgadillo et al., 2017) with 
alpha set at 0.05, the minimum required sample size is 161 
participants. It would be 105 participants to detect a similar 
effect for that found for employment status (R2 of 0.137). In 
Dep-GP there are data on 4679 participants at 3-4 months 
post-baseline or 5226 once missing outcome data have been 
imputed. These sample sizes would give 80% power to detect 
effects where R2 is greater than or equal to 0.0033 or 0.0029 
respectively, with alpha set a 0.05.
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Risk of bias
Risks of bias assessments will be conducted using the Quality 
in Prognosis Studies (QUIPS) (Hayden et al., 2013). Two 
reviewers (JB & RS) will independently rate the risk of bias 
on the QUIPS in each study related to : i) study participation; 
ii) study attrition; iii) prognostic factor measurement; iv) outcome 
measurement; v) study confounding; and vi) statistical analysis 
and reporting. Studies well then be given a rating of “high risk”, 
“moderate risk” or “low risk”. The quality of evidence for 
each prognostic indicator will be assessed using the Grading 
Recommendations, Assessment, Development and Evaluations 
(GRADE) framework (Guyatt et al., 2008).
Discussion and conclusions
Knowledge of prognosis for those seeking treatment for 
depression after accounting for baseline severity has been 
limited to the consideration of severity only as a depressive 
symptom scale score, but many other related factors including 
the chronicity of depression and comorbid symptoms of anxiety 
have been found to be important prognostic indicators. In 
addition, a number of factors have been reported to be indica-
tors of prognosis for depressed patients, but whether this is 
true after adjusting for severity encompassed in a scale score 
(symptom severity) or a more broad range of related factors 
(which here we call “disorder severity”) remains to be seen. In 
order to investigate this, data from the individual participants 
of a wide range of clinical trials which have measured this 
breadth of severity related factors is needed.
We found 13 studies that do this and met inclusion criteria, 12 
have given IPD data to help form the Dep-GP database and the 
remaining one study is in the process of doing so. We will use 
differing subsets of the 13 studies to meet our aims as necessary 
where data on key variables are available. The consistency 
in setting and the variability in both the populations drawn upon 
in the 13 studies and the treatments received in those studies 
means that findings from the Dep-GP database should be widely 
generalizable to adults with depression seeking treatment from 
their GP/family physician.
Study status
This is protocol version 1.2 last amended, 3rd April 2019. Data 
collection from eligible studies started in April 2016, agreement 
for data sharing from the final eligible study was provided on 
12th March 2019, data for that study have not been provided 
yet. Estimated time to complete the outlined analyses is six 
months from the point at which we receive the final study 
dataset or if there is any reason that it cannot be provided, six 
months from the time we are notified of that eventuality.
Dissemination
Findings from the analyses outlined above will be disseminated 
through peer-reviewed publications, and academic conference 
proceedings, through online blogs and other grey-literature and 
to appropriate service user research advisory groups linked to 
the host organisation.
Data availability
Underlying data
No data are associated with this article
Extended data
Open Science Framework: What factors indicate prognosis for 
adults with depression in primary care? https://doi.org/10.17605/
OSF.IO/UX95Q (Buckman, 2019)
This project contains the following extended data:
•    details of missing data across dep-gp studies.docx 
(Missing data from included studies)
•    Ethics approval and trial registration details for dep-gp 
studies.docx (Ethics approval and trial registration details 
of included studies)
•    Search results_OSF.docx (Search terms and results of 
searches)
Reporting guidelines
Open Science Framework: PRISMA-P checklist (Shamseer 
et al., 2015) for “What factors indicate prognosis for adults 
with depression in primary care? A protocol for meta-analyses 
of individual patient data using the Dep-GP database”. https:// 
doi.org/10.17605/OSF.IO/UX95Q (Buckman, 2019)
Data are available under the terms of the Creative Commons 
Zero “No rights reserved” data waiver (CC0 1.0 Public domain 
dedication).
Grant information
This work was supported by the Wellcome Trust through a 
Clinical Research Fellowship to JEJB [201292].
SP, KC and RS were all funded by University College London 
through the Research Department of Clinical, Educational and 
Health Psychology and respectively funded by the Higher Education 
Funding Council for England, NIHR, and the Royal Col-
lege of Psychiatrists. SP and GL, and GA were supported by 
the National Institute for Health Research University College 
London Hospitals Biomedical Research Centre. ZC was 
supported by MQ Foundation [MQDS16/72]. RJDeR was on 
the faculty in the Department of Psychology at the University 
of Pennsylvania. SH was on the faculty in the Department of 
Psychology at Vanderbilt University in Nashville Tennessee USA. 
IW was supported by the Medical Research Council Programme 
[MC_UU_12023/21]. TK was funded through the University 
of Southampton by the Higher Education Funding Council for 
England. EW was funded through the University of Exeter by 
the Higher Education Funding Council for England. SG was 
funded by grants from the National Institute for Health Research. 
The funders had no role in study design, data collection and 
analysis, decision to publish, or preparation of the manuscript.
Page 11 of 15
Wellcome Open Research 2019, 4:69 Last updated: 09 AUG 2019
References
 Beck AT, Steer RA, Brown GK: Beck depression inventory-II. San Antonio. 1996; 
78(2): 490–498.  
Reference Source
 Boschloo L, Vogelzangs N, van den Brink W, et al.: Alcohol use disorders and 
the course of depressive and anxiety disorders. Br J Psychiatry. 2012; 200(6): 
476–484.  
PubMed Abstract | Publisher Full Text 
 Buckman JEJ: What factors indicate prognosis for adults with depression in 
primary care? 2019.  
http://www.doi.org/10.17605/OSF.IO/UX95Q
 Buckman JEJ, Naismith I, Saunders R, et al.: The Impact of Alcohol Use on 
Drop-out and Psychological Treatment Outcomes in Improving Access to 
Psychological Therapies Services: an Audit. Behav Cogn Psychother. 2018; 
46(5): 513–527.  
PubMed Abstract | Publisher Full Text 
 Buckman JEJ, Underwood A, Clarke K, et al.: Risk factors for relapse and 
recurrence of depression in adults and how they operate: A four-phase 
systematic review and meta-synthesis. Clin Psychol Rev. 2018; 64(7): 13–38. 
PubMed Abstract | Publisher Full Text | Free Full Text 
 Button KS, Kounali D, Thomas L, et al.: Minimal clinically important difference 
on the Beck Depression Inventory--II according to the patient’s perspective. 
Psychol Med. 2015; 45(15): 3269–3279.  
PubMed Abstract | Publisher Full Text | Free Full Text 
 Chalder M, Wiles NJ, Campbell J, et al.: Facilitated physical activity as a treatment 
for depressed adults: randomised controlled trial. BMJ. 2012; 344: e2758.  
PubMed Abstract | Publisher Full Text | Free Full Text 
 Chekroud AM, Zotti RJ, Shehzad Z, et al.: Cross-trial prediction of treatment 
outcome in depression: a machine learning approach. Lancet Psychiatry. 2016; 
3(3): 243–250.  
PubMed Abstract | Publisher Full Text 
 Choi SW, Schalet BD, Cook KF, et al.: Establishing a common metric for 
depressive symptoms: linking the BDI-II, CES-D, and PHQ-9 to PROMIS 
depression. Psychol Assess. 2014; 26(2): 513–527.  
PubMed Abstract | Publisher Full Text | Free Full Text 
 Clarkson P, Giebel CM, Challis D, et al.: Outcomes from a pilot psychological 
therapies service for UK military veterans. Nurs Open. 2016; 3(4): 227–235. 
PubMed Abstract | Publisher Full Text | Free Full Text 
 Cohen ZD, DeRubeis RJ: Treatment Selection in Depression. Annu Rev Clin 
Psychol. 2018; 14: 209–236.  
PubMed Abstract | Publisher Full Text 
 Cohen ZD, Kim TT, Van HL, et al.: A demonstration of a multi-method variable 
selection approach for treatment selection: Recommending cognitive-
behavioral versus psychodynamic therapy for mild to moderate adult 
depression. Psychother Res. 2019; 1–14.  
PubMed Abstract | Publisher Full Text 
 Cox JL, Holden JM, Sagovsky R: Detection of postnatal depression. 
Development of the 10-item Edinburgh Postnatal Depression Scale. Br J 
Psychiatry. 1987; 150(6): 782–786.  
PubMed Abstract | Publisher Full Text 
 Delgadillo J, Huey D, Bennett H, et al.: Case complexity as a guide for 
psychological treatment selection. J Consult Clin Psychol. 2017; 85(9): 835–853. 
PubMed Abstract | Publisher Full Text 
 Delgadillo J, Moreea O, Lutz W: Different people respond differently to therapy: 
A demonstration using patient profiling and risk stratification. Behav Res Ther. 
2016; 79: 15–22.  
PubMed Abstract | Publisher Full Text 
 DeRubeis RJ, Cohen ZD, Forand NR, et al.: The Personalized Advantage 
Index: translating research on prediction into individualized treatment 
recommendations. A demonstration. PLoS One. 2014; 9(1): e83875.  
PubMed Abstract | Publisher Full Text | Free Full Text 
 Fisher DJ: Two-stage individual participant data meta-analysis and generalized 
forest plots. Stata J. 2015; 15(2): 369–396.  
Publisher Full Text 
 Fournier JC, Derubeis RJ, Hollon SD, et al.: Antidepressant drug effects and 
depression severity: a patient-level meta-analysis. JAMA. 2010; 303(1): 47–53. 
PubMed Abstract | Publisher Full Text | Free Full Text 
 Fournier JC, DeRubeis RJ, Shelton RC, et al.: Prediction of response to medication 
and cognitive therapy in the treatment of moderate to severe depression.  
J Consult Clin Psychol. 2009; 77(4): 775–787.  
PubMed Abstract | Publisher Full Text | Free Full Text 
 Fried EI, Nesse RM: The impact of individual depressive symptoms on 
impairment of psychosocial functioning. PLoS One. 2014; 9(2): e90311. 
PubMed Abstract | Publisher Full Text | Free Full Text 
 Gilbody S, Littlewood E, Hewitt C, et al.: Computerised cognitive behaviour 
therapy (cCBT) as treatment for depression in primary care (REEACT trial): 
large scale pragmatic randomised controlled trial. BMJ. 2015; 351: h5627. 
PubMed Abstract | Publisher Full Text | Free Full Text 
 Goldberg D: General Health Questionnaire (GHQ-12) NFER. Nelson Publishing 
Co. Ltd Windsor, UK. 1992. 
 Guyatt GH, Oxman AD, Vist GE, et al.: GRADE: an emerging consensus on 
rating quality of evidence and strength of recommendations. BMJ. 2008; 
336(7650): 924–926.  
PubMed Abstract | Publisher Full Text | Free Full Text 
 Hallgren M, Lundin A, Tee FY, et al.: Somebody to lean on: Social relationships 
predict post-treatment depression severity in adults. Psychiatry Res. 2017; 249: 
261–267.  
PubMed Abstract | Publisher Full Text 
 Hayden JA, van der Windt DA, Cartwright JL, et al.: Assessing bias in studies of 
prognostic factors. Ann Intern Med. 2013; 158(4): 280–286.  
PubMed Abstract | Publisher Full Text 
 Herdman M, Gudex C, Lloyd A, et al.: Development and preliminary testing of 
the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011; 20(10): 
1727–1736.  
PubMed Abstract | Publisher Full Text | Free Full Text 
 Higgins JP, Thompson SG, Deeks JJ, et al.: Measuring inconsistency in meta-
analyses. BMJ. 2003; 327(7414): 557–560.  
PubMed Abstract | Publisher Full Text | Free Full Text 
 Holmes TH, Rahe RH: The Social Readjustment Rating Scale. J Psychosom Res. 
1967; 11(2): 213–218.  
PubMed Abstract | Publisher Full Text 
 Horton NJ, Lipsitz SR: Multiple Imputation in Practice: Comparison of Software 
Packages for Regression Models With Missing Variables. Am Stat. 2001; 55(3): 
244–254.  
Publisher Full Text 
 Huibers MJH, Van Breukelen G, Roelofs J, et al.: Predicting response to 
cognitive therapy and interpersonal therapy, with or without antidepressant 
medication, for major depression: A pragmatic trial in routine practice. J Affect 
Disord. 2014; 152–154: 146–154.  
PubMed Abstract | Publisher Full Text 
 Kendrick T, Peveler R, Longworth L, et al.: Cost-effectiveness and cost-utility 
of tricyclic antidepressants, selective serotonin reuptake inhibitors and 
lofepramine: randomised controlled trial. Br J Psychiatry. 2006; 188(4): 337–345. 
PubMed Abstract | Publisher Full Text 
 Kendrick T, Simons L, Mynors-Wallis L, et al.: A trial of problem-solving by 
community mental health nurses for anxiety, depression and life difficulties 
among general practice patients. The CPN-GP study. Health Technol Assess. 
2005; 9(37): 1–104, iii.  
PubMed Abstract | Publisher Full Text 
 Kessler D, Lewis G, Kaur S, et al.: Therapist-delivered internet psychotherapy 
for depression in primary care: a randomised controlled trial. Lancet. 2009; 
374(9690): 628–634.  
PubMed Abstract | Publisher Full Text 
 Kessler DS, Macneill SJ, Tallon D, et al.: Mirtazapine added to SSRIs or SNRIs 
for treatment resistant depression in primary care: phase III randomised 
placebo controlled trial (MIR). BMJ. 2018; 363: k4218.  
PubMed Abstract | Publisher Full Text | Free Full Text 
 Kessler RC: The potential of predictive analytics to provide clinical decision 
support in depression treatment planning. Curr Opin Psychiatry. 2018; 31(1): 
32–39.  
PubMed Abstract | Publisher Full Text 
 Kessler RC, Chiu WT, Demler O, et al.: Prevalence, Severity, and Comorbidity of 
12-Month DSM-IV Disorders in the National Comorbidity Survey Replication. 
Arch Gen Psychiatry. 2005; 62(6): 617–627.  
PubMed Abstract | Publisher Full Text | Free Full Text 
 Kirsch I, Deacon BJ, Huedo-medina TB, et al.: Initial severity and antidepressant 
benefits: a meta-analysis of data submitted to the Food and Drug 
Administration. PLoS Med. 2008; 5(2): 260–268, e45.  
PubMed Abstract | Publisher Full Text | Free Full Text 
 Kroenke K, Spitzer RL, Williams JB: The PHQ-9: validity of a brief depression 
severity measure. J Gen Intern Med. 2001; 16(9): 606–613.  
PubMed Abstract | Publisher Full Text | Free Full Text 
 Leucht S, Helfer B, Gartlehner G, et al.: How effective are common medications: 
a perspective based on meta-analyses of major drugs. BMC Med. 2015; 13(1): 
253–258.  
PubMed Abstract | Publisher Full Text | Free Full Text 
 Leucht S, Hierl S, Kissling W, et al.: Putting the efficacy of psychiatric and 
general medicine medication into perspective: review of meta-analyses. Br J 
Psychiatry. 2012; 200(2): 97–106.  
PubMed Abstract | Publisher Full Text 
 Lewis G, Mulligan J, Wiles N, et al.: Polymorphism of the 5-HT transporter and 
response to antidepressants: randomised controlled trial. Br J Psychiatry. 2011; 
198(6): 464–471.  
PubMed Abstract | Publisher Full Text 
 Lewis G, Pelosi AJ, Araya R, et al.: Measuring psychiatric disorder in the 
community: a standardized assessment for use by lay interviewers. Psychol 
Med. 1992; 22(2): 465–486.  
PubMed Abstract | Publisher Full Text 
 Lutz W, Saunders SM, Leon SC, et al.: Empirically and Clinically Useful Decision 
Page 12 of 15
Wellcome Open Research 2019, 4:69 Last updated: 09 AUG 2019
Making in Psychotherapy: Differential Predictions With Treatment Response 
Models. Psychol Assess. 2006; 18(2): 133–141.  
PubMed Abstract | Publisher Full Text 
 Morris TP, White IR, Royston P: Tuning multiple imputation by predictive mean 
matching and local residual draws. BMC Med Res Methodol. 2014; 14: 75–88.  
PubMed Abstract | Publisher Full Text | Free Full Text 
 Olfson M, Blanco C, Marcus SC: Treatment of adult depression in the United 
States. JAMA Intern Med. 2016; 176(10): 1482–1491.  
PubMed Abstract | Publisher Full Text 
 Piccinelli M, Tessari E, Bortolomasi M, et al.: Efficacy of the alcohol use disorders 
identification test as a screening tool for hazardous alcohol intake and related 
disorders in primary care: a validity study. BMJ. 1997; 314(7078): 420–4. 
PubMed Abstract | Publisher Full Text | Free Full Text 
 Resche-Rigon M, White IR, Bartlett JW, et al.: Multiple imputation for handling 
systematically missing confounders in meta-analysis of individual participant 
data. Stat Med. 2013; 32(28): 4890–4905.  
PubMed Abstract | Publisher Full Text 
 Richards DA, Hill JJ, Gask L, et al.: Clinical effectiveness of collaborative care 
for depression in UK primary care (CADET): cluster randomised controlled 
trial. BMJ. 2013; 347: f4913.  
PubMed Abstract | Publisher Full Text | Free Full Text 
 Rothwell PM: Treating individuals 2. Subgroup analysis in randomised 
controlled trials: importance, indications, and interpretation. Lancet. 2005; 
365(9454): 176–186.  
PubMed Abstract | Publisher Full Text 
 Royston P: Multiple imputation of missing values: Further update of ice, with 
an emphasis on categorical variables. Stata J. 2009; 9(3): 466–477.  
Publisher Full Text 
 Royston P, White IR: Multiple Imputation by Chained Equations (MICE): 
Implementation in Stata. J Stat Softw. 2011; 45(4): 1–20.  
Publisher Full Text 
 Rush AJ, Kraemer HC, Sackeim HA, et al.: Report by the ACNP Task 
Force on response and remission in major depressive disorder. 
Neuropsychopharmacology. 2006; 31(9): 1841–1853.  
PubMed Abstract | Publisher Full Text 
 Salaminios G, Duffy L, Ades A, et al.: A randomised controlled trial assessing 
the severity and duration of depressive symptoms associated with a clinically 
significant response to sertraline versus placebo, in people presenting to 
primary care with depression (PANDA trial): study protocol for a randomised 
controlled trial. Trials. 2017; 18(1): 496–510.  
PubMed Abstract | Publisher Full Text | Free Full Text 
 Salisbury C, O'Cathain A, Edwards L, et al.: Effectiveness of an integrated 
telehealth service for patients with depression: a pragmatic randomised 
controlled trial of a complex intervention. Lancet Psychiatry. 2016; 3(6): 515–525. 
PubMed Abstract | Publisher Full Text 
 Sartorius N, Üstün TB, Lecrubier Y, et al.: Depression comorbid with anxiety: 
results from the WHO study on psychological disorders in primary health care. 
Br J Psychiatry Suppl. 1996; 168(30): 38–43.  
PubMed Abstract | Publisher Full Text 
 Saunders R, Buckman JEJ, Cape J, et al.: Trajectories of depression and anxiety 
symptom change during psychological therapy. J Affect Disord. 2019; 249: 
327–335.  
PubMed Abstract | Publisher Full Text | Free Full Text
 Saunders R, Cape J, Fearon P, et al.: Predicting treatment outcome in 
psychological treatment services by identifying latent profiles of patients.  
J Affect Disord. 2016; 197: 107–115.  
PubMed Abstract | Publisher Full Text 
 Shamseer L, Moher D, Clarke M, et al.: Preferred reporting items for systematic 
review and meta-analysis protocols (PRISMA-P) 2015: elaboration and 
explanation. BMJ. 2015; 350: g7647.  
PubMed Abstract | Publisher Full Text 
 Sharp DJ, Chew-graham C, Tylee A, et al.: A pragmatic randomised controlled 
trial to compare antidepressants with a community-based psychosocial 
intervention for the treatment of women with postnatal depression: the 
RESPOND trial. Health Technol Assess. 2010; 14(43): iii-iv, ix-xi, 1-153.  
PubMed Abstract | Publisher Full Text 
 Sherboune CD, Stewart AL: The MOS Social Support Survey. Soc Sci Med. 1991; 
32(6): 705–714.  
PubMed Abstract | Publisher Full Text 
 StataCorp LP: Stata Base Reference Manual - Release 15. College Station, 
Texas: Stata Press. 2017.  
Reference Source
 Thomas LJ, Abel A, Ridgway N, et al.: Cognitive behavioural therapy as an 
adjunct to pharmacotherapy for treatment resistant depression in primary 
care: The CoBalT randomised controlled trial protocol. Contemp Clin Trials. 
2012; 33(2): 312–319.  
PubMed Abstract | Publisher Full Text 
 Thomas HV, Lewis G, Watson M, et al.: Computerised patient-specific guidelines 
for management of common mental disorders in primary care: a randomised 
controlled trial. Br J Gen Pract. 2004; 54(508): 832–837.  
PubMed Abstract | Free Full Text 
 Thornicroft G, Chatterji S, Evans-Lacko S, et al.: Undertreatment of people with 
major depressive disorder in 21 countries. Br J Psychiatry. 2017; 210(2): 119–124. 
PubMed Abstract | Publisher Full Text | Free Full Text 
 van Hout B, Janssen MF, Feng YS, et al.: Interim scoring for the EQ-5D-5L: mapping 
the EQ-5D-5L to EQ-5D-3L value sets. Value Health. 2012; 15(5): 708–715.  
PubMed Abstract | Publisher Full Text 
 Weaver T, Madden P, Charles V, et al.: Comorbidity of substance misuse and 
mental illness in community mental health and substance misuse services. Br 
J Psychiatry. 2003; 183: 304–313.  
PubMed Abstract | Publisher Full Text 
 Zigmond AS, Snaith RP: The hospital anxiety and depression scale. Acta 
Psychiatr Scand. 1983; 67(6): 361–370.  
PubMed Abstract | Publisher Full Text 
Page 13 of 15
Wellcome Open Research 2019, 4:69 Last updated: 09 AUG 2019
 Open Peer Review
 Current Peer Review Status:
Version 1
 18 June 2019Reviewer Report
https://doi.org/10.21956/wellcomeopenres.16615.r35663
© 2019 Galante J. This is an open access peer review report distributed under the terms of the Creative Commons
, which permits unrestricted use, distribution, and reproduction in any medium, provided the originalAttribution Licence
work is properly cited.
   Julieta Galante
Department of Psychiatry, University of Cambridge, Cambridge, UK
This article proposes a meta-analysis of individual participant trial data to explore prognostic factors of
adult depression, and assess their influence independently of each other. The authors have already
secured individual participant data for almost all of the trials to be included.
I consider this manuscript to be well-written, with clear objectives and an appropriate study design.
However, regarding reproducibility, I am not clear on the implication of the review search date, which is
March 2019. I have to assume that data sharing agreements predate the search, which was only
conducted to make sure no eligible trials were missing – was the 13  trial a result of the search? It would
be much clearer if the authors could spell out this process.
Another confusing point is that the PROSPERO registration dated April 2019 shows Preliminary searches,
Piloting of the study selection process, Formal screening of search results against eligibility criteria and
Data extraction as ongoing or not started; this is inconsistent with what is stated in the manuscript.
Similarly, in the Data handling and data management section the authors wrote “data from 13 studies
were received…”. This is inconsistent with previous statements that data from one trial is pending.
Figure 1 shows that pilot/feasibility trials were excluded (see records excluded). If these were RCTs and
used a sample that was different from the larger trials that followed, it is unclear why they were excluded.
If exclusion was pre-specified and performed in a systematic fashion, it should be explained and justified
in detail as part of the exclusion criteria. If exclusion was not pre-specified systematically, then these trials
should be included in the meta-analysis, or at least this mentioned as a limitation.
Regarding generalisability, the discussion section reads: “findings from the Dep-GP database should be
widely generalizable to adults with depression seeking treatment from their GP/family physician”. I find
this too strong an assertion of generalisability - authors are only including trials from the UK, and there is
cultural variability in many of the factors measured, so I would be more cautious regarding the external
validity of the findings.
Is the rationale for, and objectives of, the study clearly described?
Yes
th
Page 14 of 15
Wellcome Open Research 2019, 4:69 Last updated: 09 AUG 2019
 Yes
Is the study design appropriate for the research question?
Yes
Are sufficient details of the methods provided to allow replication by others?
Partly
Are the datasets clearly presented in a useable and accessible format?
Not applicable
 Nonfinancial competing interests: I am a current collaborator with Ian R. White onCompeting Interests:
an unrelated project. I do not believe this has affected my objectivity when reviewing this article.
Reviewer Expertise: Systematic reviews, meta-analysis, randomised controlled trials, mental health. I
have not been able to assess the statistical methods in detail since I am not a statistician.
I confirm that I have read this submission and believe that I have an appropriate level of
expertise to confirm that it is of an acceptable scientific standard, however I have significant
reservations, as outlined above.
Page 15 of 15
Wellcome Open Research 2019, 4:69 Last updated: 09 AUG 2019
